Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.6218 +0.0177 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
What About Women? This Company Targets Female-Focused Cancers ↗
Photo sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug ↗
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.  
Via Benzinga
News headline image
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs ↗
Martin Lehr, Co-Founder and CEO of Contect Therapeutics, Inc (NASDAQ: CNTX), was a guest on Benzinga’s All Access on Aug 12, 2022. 
Via Benzinga
News headline image
40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors. Jumia Technologies AG (... 
Via Benzinga
News headline image
66 Biggest Movers From Friday ↗
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. 
Via InvestorPlace
News headline image
68 Biggest Movers From Yesterday ↗
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares... 
Via Benzinga
News headline image
26 Stocks Moving in Monday's Pre-Market Session ↗
Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 million for 2021. Twitter, Inc. (NYSE: TWTR) rose... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze. ShiftPixy... 
Via Benzinga
News headline image
25 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE... 
Via Benzinga
News headline image
32 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 31.7% to $2.41 after the company announced it was awarded a multiple award blanket purchase agreement by the United... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
20 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 48.1% to $6.77 in pre-market trading after the company entered into a Master Service Agreement with PRC Clinical,... 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
22 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
News headline image
50 Biggest Movers From Friday ↗
Gainers SigmaTron International, Inc. (NASDAQ: SGMA) jumped 84.7% to settle at $14.94 on Friday after the company reported Q2 EPS and sales results were higher year over year.... 
Via Benzinga
News headline image
36 Stocks Moving In Friday's Mid-Day Session ↗
Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) jumped 43.1% to $2.6909. American Virtual Cloud Technologies shares jumped over 82% on Thursday after the company... 
Via Benzinga
News headline image
ORCL Stock: 6 Reasons Why Oracle Investors Are Smiling Today ↗
Oracle (ORCL) stock is on the rise Friday thanks to the computer tech company's earnings report for its fiscal second quarter of 2022. 
Via InvestorPlace
News headline image
EVBG Stock: 10 Things to Know About Everbridge CEO’s Exit as Shares Plunge ↗
Everbridge (EVBG) stock is taking a beating on Friday following news that the software company's CEO is leaving for unknown reasons. 
Via InvestorPlace
News headline image
MITC Stock: The Lab-Grown Steak Breakthrough That Has MeaTech3D Looking Tasty Today ↗
MeaTech3D (MITC) stock is heating up today following news of a major breakthrough in its efforts to create 3D-printed steak. 
Via InvestorPlace
News headline image
CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today ↗
Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.